AvenCell
- Company typePrivate
- Founded2021
- HeadquartersWatertown, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
AvenCell firmographics
Firmographics- Name
- AvenCell
- Legal name
- AvenCell Therapeutics, Inc.
- Website
- https://avencell.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
AvenCell industry classification
Industry- Product category
- Allogeneic CAR-T Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where AvenCell is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
AvenCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CAR-T Cell Therapy Development and Commercialization: AvenCell is developing allogeneic CAR-T cell therapy candidates for hematologic malignancies. The company aims to commercialize off-the-shelf cell therapy products that address limitations of autologous CAR-T therapies including manufacturing timelines, costs, and accessibility.
- Co-development and Co-funding Agreements: The company has co-development and co-funding (Co-Co) agreements with Intellia Therapeutics for allogeneic universal CAR-T cell products, with Intellia having options to enter additional Co-Co agreements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AvenCell product offering
Product offeringCore offering
AvenCell is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for hard-to-treat hematologic cancers. Its pipeline combines two proprietary platforms — the Universal Switchable CAR (UniCAR/RevCAR) platform, which allows rapid on/off control of CAR-T activity through soluble Targeting Modules, and the TrueAllo allogeneic platform using CRISPR/Cas9 engineering to overcome graft-versus-host disease and host rejection. Lead candidates include AVC-201 (CD123-directed, for AML), AVC-203 (CD19/CD20 dual-targeting, for B-cell malignancies), and AVC-202 (multiple myeloma).
Product overview
AvenCell is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies for hard-to-treat cancers. The company's portfolio consists of three clinical-stage product candidates: AVC-201 (lead allogeneic CD123-directed switchable CAR-T for AML), AVC-203 (CD19/CD20 dual-targeting CAR-T for B-cell malignancies and autoimmune diseases), and AVC-202 (undisclosed target for multiple myeloma). These therapies are built on two proprietary technology platforms: the Universal Switchable CAR platform, which enables rapid on/off control of CAR-T activity via separately infused Targeting Modules, and the TrueAllo allogeneic platform, which allows the use of healthy donor cells engineered to avoid graft-versus-host disease and rejection. The company was launched in 2021 through a partnership combining GEMoaB's switchable CAR-T technology with Intellia's CRISPR/Cas9 genome editing capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- AVC-201 First-in-class CRISPR-engineered allogeneic CD123-directed switchable CAR-T therapy for relapsed/refractory acute myeloid leukemia (AML) and other CD123-positive hematological malignancies. Combines Universal Switchable CAR-T technology with the TrueAllo platform to provide an off-the-shelf product engineered to overcome graft-versus-host disease and host rejection. Currently in Phase I clinical development (RevSTAR-123 study, NCT05949125).
- AVC-203 CRISPR-engineered allogeneic CD19/CD20 dual-targeting switchable CAR-T therapy for relapsed/refractory B-cell malignancies including DLBCL, with potential expansion into autoimmune disease indications. Built on the TrueAllo platform with improved gene editing and manufacturing processes for superior CAR-T expansion and persistence. World's first CRISPR-engineered allogeneic dual-targeting switchable CAR-T.
- AVC-202
Quantifiable outcome
- Phase I proof-of-concept demonstrated efficacy signals in late-line R/R AML patients with 1 PR and 2 CRi in first 3 fully treated patients
- +2 more outcomes
Companies that use AvenCell
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles4 records
AvenCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AvenCell partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered founding/flagship, core and minor.
- Cellex Cell Professionalsfounding/flagshipContributed switchable Universal CAR-T technology developed by GEMoaB GmbH and manufacturing expertise including GMP facilities for CAR-T cell production. GEMoaB became a subsidiary of the newly established company. Cellex is a world leader in manufacturing hematopoietic blood stem cell products and leading European manufacturer for CAR-T cells.
- Intellia Therapeuticsfounding/flagshipContributed best-in-class CRISPR/Cas9 genome editing technology creating an allogeneic universal CAR-T platform. Entered into co-development and co-funding (Co-Co) agreement to develop an allogeneic universal CAR-T product. Intellia has option to enter second Co-Co agreement for selected products. Equal ownership with Blackstone and Cellex in new company.
- GEMoaB GmbHcoreAcquired as subsidiary of AvenCell. GEMoaB is the clinical-stage biopharmaceutical company that developed the UniCAR and RevCAR switchable universal CAR-T platforms. Continues to advance clinical stage CAR T-cell programs including GEM333 (CD33 bispecific antibody) and GEM3PSCA (PSCA bispecific antibody) partnered with Bristol-Myers Squibb.
- Bristol-Myers SquibbminorGlobal partnership through GEMoaB for Phase I assets GEM333 (CD33 bispecific antibody for AML) and GEM3PSCA (PSCA bispecific antibody for prostate cancer). Bristol-Myers Squibb acquired Celgene which had partnership agreements with GEMoaB.
- University Hospital Carl Gustav Carus DresdencoreAcademic medical center collaborating on clinical trials with Prof. Gerhard Ehninger (former Head of Hematology and Oncology) and Dr. Martin Wermke as principal investigators for Phase I studies.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
AvenCell competitors and assessment
Company assessmentDirect peers
- Cellectis: Cellectis is a clinical-stage biotech developing allogeneic CAR-T therapies using TALEN gene editing, with programs in AML, ALL, and other hematologic cancers. Highly comparable to AvenCell on allogeneic platform, gene editing foundation, and overlapping AML/B-cell target space.
- Atara Biotherapeutics: Atara Biotherapeutics develops allogeneic T-cell and CAR-T immunotherapies for hematologic malignancies and solid tumors, including tabelecleucel for EBV+ PTLD. Direct comparable as an allogeneic cell therapy peer focused on similar hematologic indications.
- Caribou Biosciences: Caribou Biosciences is a clinical-stage allogeneic CAR-T developer using CRISPR-based gene editing for off-the-shelf cell therapies in hematologic malignancies. Direct comparable on platform technology (CRISPR allogeneic), target indications, and clinical-stage positioning versus AvenCell.
- Allogene Therapeutics: Allogene Therapeutics is a clinical-stage biotech pioneering allogeneic CAR-T cell therapies with multiple programs in hematologic malignancies. It is the most directly comparable peer to AvenCell given shared allogeneic platform strategy, target indications (B-cell, AML), and gene-editing-enabled off-the-shelf approach.
- Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its proprietary ARCUS gene-editing platform for hematologic cancers. Comparable to AvenCell as a clinical-stage allogeneic CAR-T competitor targeting similar hematologic malignancy indications with gene-edited donor cells.
- Fate Therapeutics: Fate Therapeutics develops off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSC) for cancer and autoimmune diseases. Comparable to AvenCell on the off-the-shelf cell therapy thesis for hematologic malignancies, with a distinct but adjacent allogeneic platform approach.
- Crispr Therapeutics: Crispr Therapeutics develops gene-edited allogeneic CAR-T cell therapies including the approved Casgevy (with Vertex) and multiple clinical-stage hematology programs. Highly comparable to AvenCell via shared CRISPR/Cas9 allogeneic engineering and focus on hematologic malignancies including AML and B-cell cancers.
Emerging players
- Adicet Bio: Adicet Bio is a clinical-stage biotech developing allogeneic gamma-delta CAR-T cell therapies for hematologic malignancies and autoimmune diseases. Emerging allogeneic CAR-T peer with overlapping B-cell and autoimmune indications that AvenCell's AVC-203 also targets.
Others
- Intellia Therapeutics: Intellia Therapeutics is a co-founding partner of AvenCell and the source of the CRISPR/Cas9 allogeneic platform underlying TruAllo. While not a direct CAR-T competitor (Intellia focuses on in vivo gene editing), it is the enabling technology partner whose platform underpins AvenCell's core cell engineering capability.
Broad incumbents
- Bristol-Myers Squibb: BMS owns commercial autologous CAR-T therapies Breyanzi (CD19) and Abecma (BCMA) plus the partnership with GEMoaB through which AvenCell originated. Functions as both a strategic partner and broad incumbent competitor in the same hematologic CAR-T market AvenCell is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AvenCell social profiles
Digital presenceAvenCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
AvenCell leadership team
Management profileNumber of profiles
Profiles6 records
AvenCell subsidiaries and ownership
Company hierarchySubsidiaries1 record
AvenCell funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AvenCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AvenCell
What does AvenCell do?
AvenCell is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies for hard-to-treat hematologic cancers. Its pipeline combines two proprietary platforms — the Universal Switchable CAR (UniCAR/RevCAR) platform, which allows rapid on/off control of CAR-T activity through soluble Targeting Modules, and the TrueAllo allogeneic platform using CRISPR/Cas9 engineering to overcome graft-versus-host disease and host rejection. Lead candidates include AVC-201 (CD123-directed, for AML), AVC-203 (CD19/CD20 dual-targeting, for B-cell malignancies), and AVC-202 (multiple myeloma).
Is AvenCell a public or private company?
AvenCell is a private company. It is classified as venture growth investor backed and is currently operating.
When was AvenCell founded?
AvenCell was founded in 2021. It employs 51 to 100 people.
Where is AvenCell based?
AvenCell is headquartered in Watertown, United States, in the North America region.
How does AvenCell make money?
Two revenue lines are on record. CAR-T Cell Therapy Development and Commercialization is the primary driver. The others are co-development and Co-funding Agreements.
Who are AvenCell's main competitors?
Direct peers on record are Cellectis, Atara Biotherapeutics, Caribou Biosciences, Allogene Therapeutics, Precision BioSciences, Fate Therapeutics and Crispr Therapeutics. Adicet Bio is listed as an emerging player. Intellia Therapeutics is listed as an others. Bristol-Myers Squibb is listed as a broad incumbent.
Does AvenCell have an API?
No public API is recorded for AvenCell.
What industry is AvenCell in?
AvenCell's product category is Allogeneic CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.